
Extreme heat is a workplace hazard. We must treat it that way
In 2021, British Columbia's 'heat dome' claimed the lives of 619 people. This wasn't an isolated weather event. It was a public health disaster that exposed just how unprepared our systems are for a rapidly warming planet.
In Ontario, we've already seen multiple days under extreme heat warnings this season. It's the most vulnerable who feel it the most: seniors, children, people living in high-rises without air conditioning, and the people who work outdoors or in overheated environments. This isn't a warning about what's coming. This is a warning about what's here.
We can't afford to treat extreme heat as just another summer nuisance. These are the real and dangerous effects of climate change, and they are already costing lives and putting working people at risk.
Heat is a workplace hazard. We must treat it that way.
Whether it's a construction site, a delivery route, a farm, a factory floor or a commercial kitchen, Canadian workers are sweating it out in conditions that would be considered unsafe in any other context. Heat stress isn't the new normal. It is a serious occupational hazard, just like exposure to toxic chemicals or operating heavy machinery.
And the risks are real — heat stroke, dehydration, exhaustion, fainting. Heat exposure has also been linked to heart attacks, kidney damage, pregnancy complications and other chronic health conditions. In indoor workplaces that are already hot — such as bakeries, industrial kitchens, or warehouses without ventilation — the danger only multiplies. The effects are cumulative, meaning exposure day after day can push the body past its limit.
We need strong, enforceable heat protection regulations in every federal and provincial workplace, writes Bea Bruske
We must also talk about the workers and people affected in classrooms and long-term care homes. Just like workers in kitchens or postal routes, long-term care staff work in suffocating conditions while trying to care for some of the most heat-vulnerable people in our society. Many long-term care facilities and schools are decades old, poorly ventilated and lack adequate cooling. These are not just comfort issues. They are questions of dignity, safety and health.
Shockingly, only 30 per cent of schools in Toronto's public system have air conditioning. Educational workers and our children are trying to teach and learn in the same oppressive heat many workers are forced to labour in. Students in overheated classrooms can't concentrate, while educators are expected to perform under relentless physical stress. This isn't just a discomfort issue. It's about safety. It's about public health.
And yet, Ontario doesn't even track heat-related deaths the way Quebec and British Columbia do. That's unacceptable. Without proper surveillance and data, how can we protect people? Ontario needs to enhance its reporting of heat-related deaths, especially as climate change increases the frequency and intensity of extreme heat events. Advocates are calling for a more comprehensive approach: investigating deaths where heat is a contributing factor, and better tracking and reporting on demographics, living conditions and exposure levels. We can't manage what we don't measure. This information will help craft effective public health responses, protect the most vulnerable and hold employers and governments accountable.
We must act
We need strong, enforceable heat protection regulations in every province and federally. That means:
Requiring heat risk assessments at worksites;
Enshrining the right for workers to rest, hydrate and cool down;
Mandating shaded areas, water stations and proper protective equipment;
Training employers and workers to recognize the signs of heat stress;
And empowering joint health and safety committees to take real action when heat hazards arise.
Workers also need the power to refuse unsafe work when it's too hot, without fear of reprisal. That means strong enforcement, clear definitions, and real accountability for employers who fail to act.
We also need our public infrastructure to catch up with this new reality. That includes investments in cooling stations, retrofitting social housing and schools, and ensuring frontline responders are equipped to deal with the increasing health impacts of climate change.
No one should have to put their health at risk for a paycheque.
As temperatures continue to rise, so must our standards. We must ensure that all workers are protected, not just in theory, but in practice. Because the next heat wave shouldn't come with another death toll. It should come with a worker-centred plan.
Workers built this country. The least we can do is keep them safe — on the job, and in their communities.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Cision Canada
an hour ago
- Cision Canada
Little Bellies Expands Canadian Lineup with New Organic, Age-and-Stage Appropriate Snacks for Babies and Toddlers Français
New products rolling out at Loblaws and Walmart offer more adventurous tastes, textures and shapes to support independence and developmental milestones TORONTO, July 16, 2025 /CNW/ -- Little Bellies, Australian-founded baby and toddler snack brand known for its wholesome, age-and-stage appropriate snacks, is further expanding its Canadian range with seven new products designed to support key developmental milestones from 10+ months to toddlerhood. With its existing line catering to babies from 7+ months – including the well-loved puffs, Pick-Me Sticks, and Round-a-Bouts, the lineup has now grown to offer more variety for the 10+ and 12+ months stages. These new additions bring more shapes, flavours and textures that encourage independence and confident self-feeding skills. Now available at Loblaws and Walmart stores nationwide, the expanded range continues Little Bellies' mission to evolve with little ones as they grow. For 10+ Months: More to Explore Range At around 10 months, babies begin mastering rotary jaw movements, making chewing easier and allowing for more textured foods. This stage also brings growing independence in self-feeding. The More To Explore range is designed to support these milestones with melt-in-the-mouth developmentally supportive snacks that encourage chewing, promote fine motor skills and introduce babies to a wider variety of flavours and shapes. In addition to Little Bellies' beloved 10+ months Yogurt Pick-Me Sticks and Softcorn, the More to Explore range now includes: Organic Carrot & Cinnamon Paws Organic Pear & Vanilla Paws For 12+ Months: Toddlers in Training Range By 12 months, toddlers begin to rely more on solid food as part of their daily feeding routine. The Toddlers In Training range supports this growth by introducing more adventurous shapes, flavours and textures – designed to build independence and confidence at mealtimes. In addition to the 12+ months cookies, the updated lineup includes: Building on its growing presence in Canada, Little Bellies continues to expand its range and retail reach to meet the evolving needs of families. The Australian-founded brand remains committed to its mission of creating snacks that grow with children, while supporting parents as their partner in their children's feeding journey with trusted, organic and wholesome options. "With our expanded Canadian lineup and retail presence, we're excited to reach even more families with snacks that truly support a child's unique journey of development and discovery," said Clive Sher, co-founder and managing director of Little Bellies. "We continue to grow with Canadian families and provide options they feel good about – offering new ways to nurture curiosity, independence and a love of food in little ones. At Little Bellies, we do what's natural, so parents can do what's natural." Founded in 2011 by brothers Clive and Steven Sher – after Steven's son was diagnosed with severe food sensitivities – Little Bellies was created to offer natural snacks that nurture independence, encourage safe self-feeding and support palate development, without artificial additives or unnecessary ingredients. All Little Bellies products are crafted with carefully selected, organic ingredients and free from artificial colours, flavours and additives. Designed to grow with children from starting solids to toddlerhood, Little Bellies helps parents simplify snack time with developmentally supportive options they can trust. For more information, visit or connect with the brand on Instagram, TikTok or Facebook. About Little Bellies The Little Bellies brand was created by two brothers with seven young children between them, after one of their children was diagnosed with severe food sensitivities. The safe snack options at the time were significantly limited which drove their passion and awareness to develop foods with wholesome ingredients. They wanted to feed their families nothing but the best quality food, free from artificial additives, genetically modified ingredients, unnecessary salt and sugar and with minimal herbicides and pesticides, especially during the formative baby and toddler years. Little Bellies is a brand that understands the joy and challenges of raising happy, healthy children and is committed to creating wholesome snacks that delight little taste buds and make parents smile. As one of the largest baby and toddler snack suppliers in Australia and New Zealand, Little Bellies expanded into the North American market in 2019. For more information, visit


Vancouver Sun
3 hours ago
- Vancouver Sun
Cheaper generic Ozempic is coming to Canada after Novo Nordisk fails to maintain patent in this country
In what Science magazine has dubbed 'Novo Nordisk's Canadian Mistake,' Ozempic is soon to come off patent in Canada, opening the door to cheaper generic copycats, after the drug giant reportedly failed to pay a few hundred dollars in annual fees to maintain the patent rights before the weight-loss drug became a blockbuster seller. As Science reported, a patent, once lapsed, can't be restored. Novo Nordisk will continue to hold its U.S. patent until 2032. Ozempic was already the third most prescribed drug in Canada last year with 7,390,000 prescriptions dispensed, a 17 per cent increase over 2023, according to drug analytics research firm IQVIA. Start your day with a roundup of B.C.-focused news and opinion. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Sunrise will soon be in your inbox. Please try again Interested in more newsletters? Browse here. Several applications for generic semaglutide, the active compound in Novo Nordisk's injectable drugs Ozempic and Wegovy, are now before Health Canada. Last week, a U.S. telehealth service announced plans to expand into Canada next year and offer generic semaglutide at a significant discount. Richard Saynor, the head of Sandoz, a global leader in generic and biosimilar drugs, told Endpoint News in June that his company has filed for approval for a generic semaglutide in Canada once Novo Nordisk's patent exclusivity expires 'sometime in Q1 next year.' Canada is the globe's second-biggest semaglutide market, Saynor told Endpoint News. 'You gotta ask why. I don't think Canadians are disproportionately large. There's clearly a dynamic, like insulin, with cross-border business,' he said. Americans with diabetes have crossed into Canada to buy insulin at much lower prices. Ozempic and Wegovy cost about $5,000 per year. If money is no longer a factor, if chemically-identical drugs are cheaper and more affordable, 'that's going to change the calculus for many people,' said Justin Lehmiller, a senior research fellow at Indiana University's Kinsey Institute and co-author of a new survey exploring the impact that weight-loss drugs — formally known as GLP-1 agonists — are having on dating and intimacy. The survey of 2,000 single Americans (aged 18 to 91) led by Kinsey with found eight per cent reported having used a GLP-1 medication for weight loss in the past year. Among the GLP-1 users, 16 per cent said exes had reached out to reconnect, 14 per cent said they were getting more matches on dating apps and 12 per cent said they were going on more dates. The drugs seemed to be doing more to booster 'online dating success' for men than for women, the researchers said. 'Some of the studies and research that I've seen suggest that men only match one in 100 times on dating apps where for women, it's more like one in 10,' Lehmiller said. 'An attractiveness boost for men, which often accompanies using these drugs, could translate into a much bigger impact for them in the world of dating.' Men, however, were nearly twice as likely to women to say they feared being judged or shamed for taking Ozempic or other GLP-1 drugs. 'There are some masculinity concerns that are tied up in this,' said Lehmiller, a social psychologist. Men might worry about being accused of cheating, he said. 'It might be viewed as a sign of weakness for turning to a drug as opposed to losing weight through 'hard work.'' About half of the GLP-1 users also said the medications impact their sex lives, in both positive and negative ways: 18 per cent said their sexual desire increased, while 16 per cent said it dropped. Sixteen per cent said their sexual function improved; 12 per cent said it worsened. It's a nuanced picture, Lehmiller said. 'These drugs seem to be affecting different people in different ways.' 'And I think that makes sense: There is a lot of variability in the side effects people experience on these drugs.' More side effects might mean more negative impact on intimacy, he said. The drugs have also been associated with a slightly higher risk o f erectile dysfunction and testosterone deficiency in men taking semaglutide for obesity compared to men not taking the drug. About one in five in the dating survey said the drugs are creating more stigma against being overweight. 'Changing standards of attractiveness might be creating more pressure for people to look a certain way or use these medications,' Lehmiller said. A study published this week in the Canadian Medical Association Journal found 32.7 per cent of adults in Canada (10.6 million people) were obese in 2023, an eight per cent jump over 2009. Generic versions of semaglutide won't be as cheap as Aspirin. They'll still require a doctor's prescription, said Dr. Hertzel Gerstein, an endocrinologist and professor in McMaster University's department of medicine. 'Like all drugs it's a powerful drug that can have side effects and people need to be instructed on the proper way to take the drug, what to expect and what to do.' 'Is it possible that more people would be willing to pay out of pocket if they don't have insurance coverage for the drug? Sure, if it's cheaper,' Gerstein said. 'There may be more demand for it. People need to understand the risks and benefits.' Taken once a week by injection, Ozempic and Wegovy work by mimicking a hormone — glucagon-like peptide-1 — the small intestine releases when people eat. GLP-1 tricks the body into thinking it's full. It works on the brain to reduce appetite and interest in continuing to eat, and works on the stomach to slow how fast it empties so that food lingers in the stomach longer. Semaglutide has been studied extensively, Gerstein said. The amount of weight lost is related to the dosage: the higher the dose, the more weight dropped. In people with type 2 diabetes, the drug can reduce the need for insulin, or the dosage. 'But most importantly these drugs unequivocally reduce the future risk of serious health outcomes, including heart attacks, strokes, death from cardiovascular causes' and heart failure symptoms when used long-term, 'in the two- to five-year window of time,' Gerstein said. A major analysis published earlier this year based on health data from more than two million Americans veterans with diabetes found that, compared to more traditional drugs, GLP-1 use was associated with a reduced risk of substance use (alcohol, cannabis, stimulants and opioids), psychotic disorders such as schizophrenia, seizures, several respiratory conditions and neurocognitive diseases like Alzheimer's and dementia. The magnitude of the associated benefits — about a 10 to 20 per cent reduction for most outcomes — was modest, according to a background release, though the researchers said they don't 'negate' the potential value of the drugs. There were, however, several drawbacks, including an increased risk of gastrointestinal disorders (nausea, vomiting, diarrhea), low blood pressure, fainting, arthritic disorders, kidney disorders and drug-induced pancreatitis associated with GLP-1 drugs compared to usual care. Nothing is guaranteed, Gerstein said. 'I always tell patients we don't know exactly what it'll do in you. And weight loss, if it's going to happen, usually takes a month or two to start' and plateaus at around eight months. People don't lose weight indefinitely. 'There's definitely a plateau. You do not keep losing weight,' he said. The drugs yield an average weight loss of around 15 per cent, and weight can also rebound rapidly once the drugs are stopped. Ozempic has been approved in Canada for diabetes but is often used 'off label' for obesity. Wegovy has been approved for obesity. In an email to National Post, Novo Nordisk, the only current company in Canada with Health Canada-approved products containing semaglutide, said 'all intellectual property decisions are carefully considered at a global level. 'Periods of exclusivity for pharmaceutical products end as part of their normal lifecycle and generic treatments may become available over time.' 'Currently, no Health Canada-approved generic versions of semaglutide exist and we cannot speculate on other manufacturers' plans,' the company said. National Post Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our newsletters here .


Edmonton Journal
3 hours ago
- Edmonton Journal
Cheaper generic Ozempic is coming to Canada after Novo Nordisk fails to maintain patent in this country
In what Science magazine has dubbed 'Novo Nordisk's Canadian Mistake,' Ozempic is soon to come off patent in Canada, opening the door to cheaper generic copycats, after the drug giant reportedly failed to pay a few hundred dollars in annual fees to maintain the patent rights before the weight-loss drug became a blockbuster seller. Article content As Science reported, a patent, once lapsed, can't be restored. Novo Nordisk will continue to hold its U.S. patent until 2032. Article content Article content Ozempic was already the third most prescribed drug in Canada last year with 7,390,000 prescriptions dispensed, a 17 per cent increase over 2023, according to drug analytics research firm IQVIA. Article content Article content Several applications for generic semaglutide, the active compound in Novo Nordisk's injectable drugs Ozempic and Wegovy, are now before Health Canada. Last week, a U.S. telehealth service announced plans to expand into Canada next year and offer generic semaglutide at a significant discount. Article content Richard Saynor, the head of Sandoz, a global leader in generic and biosimilar drugs, told Endpoint News in June that his company has filed for approval for a generic semaglutide in Canada once Novo Nordisk's patent exclusivity expires 'sometime in Q1 next year.' Article content Canada is the globe's second-biggest semaglutide market, Saynor told Endpoint News. 'You gotta ask why. I don't think Canadians are disproportionately large. There's clearly a dynamic, like insulin, with cross-border business,' he said. Americans with diabetes have crossed into Canada to buy insulin at much lower prices. Article content Article content Ozempic and Wegovy cost about $5,000 per year. If money is no longer a factor, if chemically-identical drugs are cheaper and more affordable, 'that's going to change the calculus for many people,' said Justin Lehmiller, a senior research fellow at Indiana University's Kinsey Institute and co-author of a new survey exploring the impact that weight-loss drugs — formally known as GLP-1 agonists — are having on dating and intimacy. Article content The survey of 2,000 single Americans (aged 18 to 91) led by Kinsey with found eight per cent reported having used a GLP-1 medication for weight loss in the past year. Article content Among the GLP-1 users, 16 per cent said exes had reached out to reconnect, 14 per cent said they were getting more matches on dating apps and 12 per cent said they were going on more dates. The drugs seemed to be doing more to booster 'online dating success' for men than for women, the researchers said.